WHO forecasts promising Ebola vaccine
Hilleman Laboratories in Singapore announced the launch of a new candidate vaccine against a rare strain of Ebola known as "Bundibugyo," which currently has no approved treatment or vaccine. This vaccine, based on the "rVSV" platform used in the approved Ervebo Ebola vaccine, is considered the most promising candidate to combat an outbreak in the Democratic Republic of the Congo. The new vaccine features the ability to be stored for months at standard temperatures, making it easier and more cost-effective to distribute, especially in remote areas, compared to Ervebo, which requires ultra-low temperature storage. Development of the vaccine is currently being accelerated to begin human clinical trials.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)